Publication: 2970

Publication: 2970

Incidence of late recurrence in hormone receptor-positive or negative HER2-positive breast cancer receiving adjuvant trastuzumab: The combined analysis of the NCCTG (Alliance) N9831 and NSABP (NRG) B31 Trials

URL

URL

Google Scholar

Citation:: Cancer Res vol 79 (4_suppl) abstr PD3-02

Meeting Instance:: SABCS 2018
Year:: 2018
Type:: Abstract
Sub type:: Poster Discussion
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No

Parents:: None
Children:: 3041

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882, U24CA196171; NRG- U10CA180868 (NCTN), UG1CA189867 (NCORP), U10CA180822 (NRG Oncology SDMC [Biostats]), U24CA196067 (BSB) (Lab)

Corr. Author:
Authors:: Saranya Chumsri Zhou Li Daniel J. Serie Afshin Mashadi-Hossein Gerardo Colon-Otero Nan Song Katherine L. Pogue-Geile Patrick Gavin Soon Paik Alvaro Moreno-Aspitia Edith A. Perez E. Aubrey Thompson

Networks:: LAPS-MN026, PR028

Study
Multiple Studies, or Legacy Studies in Alliance Study:: NCCTG-N9831, NSABP B-31
Phases:: 3

Keywords: